"Lopinavir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An HIV protease inhibitor used in a fixed-dose combination with RITONAVIR. It is also an inhibitor of CYTOCHROME P-450 CYP3A.
Below are MeSH descriptors whose meaning is more general than "Lopinavir".
Below are MeSH descriptors whose meaning is more specific than "Lopinavir".
This graph shows the total number of publications written about "Lopinavir" by people in this website by year, and whether "Lopinavir" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Lopinavir" by people in Profiles.
Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia. J Biomech. 2016 09 06; 49(13):2584-2592.
Mortality and long-term virologic outcomes in children and infants treated with lopinavir/ritonavir. Pediatr Infect Dis J. 2013 Dec; 32(12):e466-72.
Quantized water access to the HIV-1 protease active site as a proposed mechanism for cooperative mutations in drug affinity. Biochemistry. 2012 Aug 21; 51(33):6487-9.
Beneficial effects of a switch to a Lopinavir/ritonavir-containing regimen for patients with partial or no immune reconstitution with highly active antiretroviral therapy despite complete viral suppression. AIDS Res Hum Retroviruses. 2011 Jun; 27(6):659-67.
Head-to-head comparison of two first-line regimens and an NRTI-sparing regimen for initial therapy of HIV-1 infection: what should we start? Curr HIV/AIDS Rep. 2009 Feb; 6(1):1-2.
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis. 2004 Jul 15; 190(2):280-4.
Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl. 2003 Sep; 9(9):954-60.
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003 Mar; 22(3):216-24.